Treatment-specific symptoms as measured on the four-item Medical Outcomes Study Short Form-36 (SF-36) and Vitality scale [clinicaltrials_resource:6b61be75f026df2c5b87077f68994cc2]
Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Treatment-specific symptoms as measured on the four-item Medical Outcomes Study Short Form-36 (SF-36) and Vitality scale [clinicaltrials_resource:6b61be75f026df2c5b87077f68994cc2]
Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
Bio2RDF identifier
6b61be75f026df2c5b87077f68994cc2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6b61be75f026df2c5b87077f68994cc2
measure [clinicaltrials_vocabulary:measure]
Treatment-specific symptoms a ...... -36 (SF-36) and Vitality scale
description
Patients continue CAD therapy ...... bsence of disease progression.
identifier
clinicaltrials_resource:6b61be75f026df2c5b87077f68994cc2
title
Treatment-specific symptoms a ...... -36 (SF-36) and Vitality scale
@en
type
label
Treatment-specific symptoms a ...... 1be75f026df2c5b87077f68994cc2]
@en